Kreuter, M. et al., "Impact of comorbidities on the course and management of idiopathic pulmonary fibrosis," European Respiratory Review, vol. 26, no. 145, pp. 170071, 2017.
King Jr, T. E., Pardo, A., & Selman, M., "Idiopathic pulmonary fibrosis," Lancet, vol. 378, no. 9807, pp. 1949-1961, 2011.
V D'Agnano, DF Mariniello, R Pagliaro, MS Far… - Drugs, 2024
… In this review, we have focused on the role of sirtuins in the pathogenesis of idiopathic and secondary pulmonaryfibrosis and their … Idiopathicpulmonaryfibrosis (IPF) is the most prevalent idiopathic interstitial lung disease and is more …
H Lee, SY Kim, YS Park, SM Choi, JH Lee, J Park - Scientific Reports, 2024
… Idiopathicpulmonaryfibrosis (IPF) is a chronic fibrosing interstitial lung disease of unknown etiology, with a poor prognosis 1 . Although IPF … Assessment of IPF severity typically involves pulmonary function tests (PFTs) and chest imaging studies …
AC Zamora, LJ Wesselius, MB Gotway, HD Tazelaar… - Seminars in Respiratory and …, 2024
… Before categorizing the ILD as idiopathicpulmonaryfibrosis (IPF), it is essential to consider and exclude identifiable causes or associations, such as inhalation exposures, drug toxicity, and SARDs.[2] Even though ILDs could be the initial …
RM El-fawakry, F Zaiton, AM Alsowey, RA Frere… - European Journal of Radiology
… Patients were classified into idiopathicpulmonaryfibrosis (IPF) (n = 14) and non-IPFILD (n = 97) groups based on clinical diagnoses determined by multidisciplinary discussion. Association between ILD-RADS categories and clinical diagnoses was …
… Idiopathicpulmonaryfibrosis (IPF) is the most common subtype of interstitial lung disease, characterized by chronic progressivepulmonaryfibrosis… Numerous studies have suggested an association between adipokines and IPF. However, due …
T Pan, L Bai, D Zhu, Y Wei, Q Zhao, F Feng, Z Wang… - PLOS ONE, 2024
… Numerous metabolomic studies have confirmed the pivotal role of metabolic abnormalities in the development of idiopathicpulmonaryfibrosis(IPF). Nevertheless, there is a lack of evidence on the causal relationship between circulating …
B An, Y Fang, L Wang, W Nie, M Wang, H Nie, C Wu… - Bioorganic Chemistry, 2024
The incidence of idiopathicpulmonaryfibrosis(IPF) has been steadily increasing each year, posing significant challenges in its treatment. In this study, we conducted the design and synthesis of 23 new inhibitors that specifically target the TGF-β1/Smad3 …
…, I Noth, A Manichaikul, IPF Survival GWAS Consortium - American Journal of …, 2024
… Idiopathicpulmonaryfibrosis (IPF) often leads to chronic respiratory failure and early death. With only two drugs known to slow IPFprogression, further understanding of factors contributing to its pathogenesis and progression is needed …
H Hayek, O Rehbini, B Kosmider, T Brandt, W Chatila… - American Journal of …, 2024
… Abstract Idiopathicpulmonaryfibrosis (IPF) is a chronic and progressive disease caused by an … Our results suggest that IPF-derived exosomes containing miR-143-5p and miR-342-5p … This study highlights the importance of exosomes in IPF …
W Zhu, C Tan, J Zhang - Biomolecules & biomedicine
… Idiopathicpulmonaryfibrosis (IPF) is a progressive and chronic disease that significantly impacts patient quality of life, and its incidence is … and its subsequent effect on IPF development. We generated a bleomycin-induced pulmonaryfibrosis …
L Calandriello - American Journal of Respiratory and Critical Care …, 2024
… Quantification of lung abnormalities on high resolution CT (HRCT) images in patients with idiopathicpulmonaryfibrosis (IPF) has been a … First, the deep learning models proposed were tested on the PROFILE dataset, a large prospective …
KS Bongers, A Massett, DN O'Dwyer - Seminars in Respiratory and Critical Care …, 2024
… [15] Idiopathicpulmonaryfibrosis (IPF) is a poorly understood form of ILD without a clear etiological association.[15] Key studies in … The respiratory microbiome in chronic hypersensitivity pneumonitis is distinct from that of idiopathicpulmonary …
M Lin, J Wang, J Wei, Y Yao, C Tang, W Jin, W Yuan… - European Journal of …, 2024
… Idiopathicpulmonaryfibrosis (IPF) is a progressive interstitial lung disease with unknown etiology and treatment options for it were limited. Whether Gastroesophageal reflux disease (GERD) could affect the occurrence of IPF …
M Tian, X Zhu, L Ren, X Zhou, L GU, K Meng, Y Tian… - European Journal of …, 2024
… Idiopathicpulmonaryfibrosis (IPF) is a chronic progressive and life-threatening interstitial lung … of IPF is depressing since an expected mean survival for patients upon diagnosis being 2–5 years only [3, 4]. There are no effective drugs to halt or …
CY Wang, L Liu, H Peng, H Luo - QJM: An International Journal of Medicine, 2024
… IdiopathicPulmonaryfibrosis is a progressive pulmonary disorder with a high mortality rate. PARN is a telomere-related pathogenic gene associated with Idiopathicpulmonaryfibrosis (IPF). Here, A novel PARN variant (NM_002582.3: p …
A Koike, K Hayashi, K Fujimori - European journal of pharmacology
… Acute exacerbation (AE) of IPF is characterized by progressive lung fibrosis with the irreversible lung function decline and inflammation, … mechanisms in AE of IPF are still not fully understood. In this study, we investigated the mechanism underlying …
A Amirkhosravi, M Mirtajaddini Goki, MR Heidari… - Scientific Reports, 2024
… Pirfenidone (PFD), one acceptable medication for treating idiopathicpulmonaryfibrosis (IPF), is not well tolerated by patients at full doses. Hence, employing of some approaches such as combination therapy may be applicable for increasing …
… to the progression of idiopathicpulmonaryfibrosis (IPF). Curcumin (CCM) in inhibits the progression of pulmonaryfibrosis by regulating the … Pulmonaryfibrosis was determined using micro-computed tomography and transmission electron …
… Decade before, pifenidone and 14 nintedanib were approved for idiopathicpulmonaryfibrosis, but no more drugs are yet available. To 15 … Idiopathic 51 pulmonaryfibrosis (IPF) is the most common type of fibrosing ILD. In 2016, Raghu et …
S Barth, C Edwards, G Saini, Y Haider, NP Williams… - Respiratory Research, 2024
… Idiopathicpulmonaryfibrosis (IPF) is the most common idiopathic ILD [1]. Usual clinical monitoring of patients with IPF is outlined in … Antifibrotic therapy such as nintedanib or pirfenidone has been shown to slow the physiological decline …
R Pal, A Barney - Biomedical Signal Processing and Control, 2024
… : (a) a longitudinal dataset recorded from 19 subjects with a diagnosis of idiopathicpulmonaryfibrosis (IPF), (b) a cross-sectional dataset … recordings from 41 subjects with wheeze (9 with chronic obstructive pulmonaryfibrosis and 32 with …
L Byrne, C McCarthy, A Fabre, N Gupta - Seminars in Respiratory and Critical Care …, 2024
… idiopathicpulmonaryfibrosis (IPF), pirfenidone and nintedanib, has not been well established in patients with SjD-ILD. Treatment with pirfenidone was associated with an almost 50% relative reduction in the rate of decline in FVC compared with …
M BEN ABDALLAH, S Bahri, N Afef, M Mona, H Linda… - Chemistry & Biodiversity
… Idiopathicpulmonaryfibrosis (IPF) is a chronic interstitial pneumonia that leads to acute lung … (HO) on an experimental model of pulmonaryfibrosis induced by bleomycin (BLM) in Wistar … In conclusion, OCE and HO exhibit antifibrotic effects …
Y Bao, S Yang, H Zhao, Y Wang, K Li, X Liu, W Zhang… - BMC Pulmonary Medicine, 2024
… Studies have shown that mitochondrial function and macrophages may play a role in the development of idiopathicpulmonaryfibrosis(IPF… of IPF pathogenesis and to find genes associated with IPF pathogenesis we performed differential …
X Yang, H Wang, A Liu, Y Ni, J Wang, Y Han, B Xie… - 2024
… Idiopathicpulmonaryfibrosis (IPF) is a chronic and progressive disorder with an estimated median survival time of 3-5 years after diagnosis[1]. Patient with IPF is characterized by restrictive ventilatory dysfunction, progressively deteriorated …
SK Tirunavalli, SB Andugulapati - Life Sciences, 2024
… Idiopathicpulmonaryfibrosis (IPF) is a chronic, progressive condition with unknown aetiology that causes the lung parenchyma to scar incessantly, lowering the quality of life and hastening death. In this investigation, we studied the anti-fibrotic …
MB Abdallah, S Bahri, N Afef, M Mona, H Linda… - Chemistry & biodiversity
… Idiopathicpulmonaryfibrosis (IPF) is a chronic interstitial pneumonia with acute lung damage … (HO) on an experimental model of pulmonaryfibrosis induced by bleomycin (BLM). Wistar rats … In conclusion, OCE and HO exhibit antifibrotic …
C Shao, NX Xia, Y Zhen, X Zhang, N Yan, Q Guo - Frontiers in Immunology
… Abstract Objectives: Interstitial lung disease (ILD) is one of the common extramuscular involvement in idiopathic inflammatory myopathies (… Univariate and multivariate Cox analyses were performed to identify the variables significantly …
X Cao, C Yu, S Cheng, Y Wang, Z Zhang, J Huang - ACS Applied Materials & …, 2024
… of fibroblasts are significant for improving the therapeutic effect of idiopathicpulmonaryfibrosis (IPF). To this aim, ionizable liposome … IPF therapy. ASNPs showed high loading and intracellular delivery efficiency for AST and siTGF-β1. After …
A Ramirez, A Kashem, H Kehara, R Yanagida… - The Journal of Heart and …, 2024
… Idiopathicpulmonaryfibrosis (IPF) remains the primary reason for lung transplant. This study investigated how lung allocation score and age of recipient affect patient survivability in patients diagnosed with IPF … to result 416 patients diagnosed with …
H Wenjie, W Zitao, G Fei, W Dong, C Jingyu - The Journal of Heart and Lung …, 2024
… Purpose: Idiopathicpulmonaryfibrosis (IPF) is a chronic interstitial fibrosing pneumonia of unknown cause, leading to a poor prognosis. It … by reanalyzing the ScRNA data from the GEO database of normal and IPF patients. Using the cell chart …
HLA Pereira, EV Mancuzo, GA Ribeiro-Samora… - Physiotherapy Theory and …, 2024
… cardiopulmonary exercise testing is the gold standard for assessing functional capacity in patients with idiopathicpulmonaryfibrosis (IPF). … Idiopathicpulmonaryfibrosis (IPF) is a progressive chronic respiratory disease characterized by a typical …
HJ Lee, K Bernau, TJ Harr, ZT Rosenkrans, GA Kessler… - Science Advances, 2024
… Idiopathicpulmonaryfibrosis (IPF) is a chronic lung disease resulting in irreversible scarring within the lungs. … Idiopathicpulmonaryfibrosis (IPF) is a chronic and progressive lung disease that results in irreversible scarring within the …
K Moghbeli, M Lipp, A Craig, J Sembrat, M Bueno… - The Journal of Heart and …, 2024
… =3), non-diseased lungs (N=3), and from patients with idiopathicpulmonaryfibrosis (N=3). Flow cytometry was performed on control and transplant … Results: T cells from explanted CLAD lungs, when compared to control and IPF lungs …
T Ueda, K Takamochi, M Fukui, T Ichikawa, A Hattori… - European Journal of Cardio …, 2024
… Idiopathicpulmonaryfibrosis, the most common and severe form of ILD, is characterized by progressive fibrosis of the lung parenchyma (5,6) and is associated with a higher incidence of lung cancer (7,8). However, the limited treatment options …
MH Pierre-Louis, A Susnjar, M Allison, YI Zhou… - The Journal of Heart and …, 2024
… Our group has utilized dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in patients with idiopathicpulmonaryfibrosis and other lung diseases, to detect changes reflective of the microvasculature and the extravascular extracellular space …
… An 84-year-old male with history of idiopathicpulmonaryfibrosis presented with an abrupt decline in mental status requiring intubation, in the setting of weeks of progressive dysphagia, ataxia, and lower extremity weakness. He followed some …
